PJT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PJT Partners is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to invest. The stock has some positive momentum and supportive analyst commentary, but the technical picture is mixed, insider selling is notable, and there is no recent news or financial quarter data to confirm a fresh fundamental catalyst. Since the user is impatient and does not want to wait for ideal entry points, my direct view is to hold off on buying today.
PJT closed at 162.99 with a 4.53% gain, which shows short-term strength. The MACD histogram is positive and expanding, indicating improving momentum. However, RSI_6 at 70.665 is near overbought territory, while the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend is still not fully confirmed as bullish. Price is also near resistance at R1 161.516 and just below R2 166.562, so upside may be limited in the near term. Overall, the chart suggests a rebound, but not a clean long-term entry yet.
["Analyst sentiment has improved recently, with Keefe Bruyette upgrading PJT to Outperform and raising the target to 175.", "UBS and Keefe Bruyette both raised price targets in late April, showing continued analyst interest.", "MACD momentum is positive and expanding, indicating the stock may still have near-term upward energy.", "The stock gained 4.53% on the day despite the S&P 500 being down 0.13%, showing relative strength."]
["Insiders are selling, and selling increased 532.54% over the last month, which is a meaningful negative signal.", "The moving-average structure is still bearish, with SMA_200 above shorter averages.", "RSI is elevated, reducing appeal for an immediate entry after the recent move up.", "No news catalysts in the recent week means there is no fresh event-driven reason to chase the stock.", "Hedge funds are neutral with no significant recent trading trend.", "The stock trend model shows only a 33.33% chance of a small next-day gain and a projected negative return over the next month."]
No latest-quarter financial snapshot was available because the financial data returned an error, so I cannot assess recent revenue or earnings growth directly. The latest quarter season is therefore not provided in the data.
Analyst trend is modestly positive. UBS kept a Neutral rating but lifted the target to 160 from 152, while Keefe Bruyette raised its target to 175 from 166 and kept Outperform. Earlier in April, Keefe Bruyette upgraded PJT to Outperform from Market Perform, which is constructive. Wall Street is somewhat split: the bull case is improving large-cap strategic M&A exposure, while the cautious view is that broader boutique results remain softer.
